(b)   binding said HLA-B7 molecule and said peptide.

201. (Once Amended) The method of claim 177, wherein said epitope is selected from the group consisting of: LPENNVLSPL (SEQ ID NO:13), APAPAPSWPL (SEQ ID NO:14), SPALNKMFCQL (SEQ ID NO:15), RPILTIITL (SEQ ID NO:17), LPPGSTKRAL (SEQ ID NO:18), SPQPKKKPL (SEQ ID NO:19), and KPLDGEYFTL (SEQ ID NO:20).

202. (Once amended) The method of claim 201, wherein said epitope is LPENNVLSPL (SEQ ID NO:13).

203. (Once amended) The method of claim 201, wherein said epitope is APAPAPSWPL (SEQ ID NO:14).

204. (Once amended) The method of claim 201, wherein said epitope is SPALNKMFCQL (SEQ ID NO:15).

205. (Once amended) The method of claim 201, wherein said epitope is RPILTIITL (SEQ ID NO:17).

206. (Once amended) The method of claim 201, wherein said epitope is LPPGSTKRAL (SEQ ID NO:18).

207. (Once amended) The method of claim 201, wherein said epitope is SPQPKKKPL (SEQ ID NO:19).

208. (Once amended) The method of claim 201, wherein said epitope is KPLDGEYFTL (SEQ ID NO:20).

209. (Once amended) A method of binding a human leukocyte antigen (HLA)-B7 molecule with a peptide comprising an epitope of p53, comprising:

(a)   contacting said HLA-B7 molecule with a peptide comprising an epitope selected from the group consisting of: GTRVRAMAI (SEQ ID NO:16) and GSRAHSSHL (SEQ ID NO:21); wherein said peptide is 8-11 amino acids in length; and thereby

(b)   binding said HLA-B7 molecule and said peptide.

212. (Once amended) The method of claim 209, wherein said epitope is GTRVRAMAI (SEQ ID NO:16).

213. (Once amended) The method of claim 209, wherein said epitope is GSRAHSSHL (SEQ ID NO:21).